Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Arcutis Biotherapeutics Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 143 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $15.89 |
|---|---|
| 52-week range | $14.16 - $38.49 |
| 50-day moving average | $18.02 |
| 200-day moving average | $23.12 |
| Wall St. target price | $53.43 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.89 from 2022-01-24
| 1 week (2022-01-18) | -1.24% |
|---|---|
| 1 month (2021-12-23) | -20.95% |
| 3 months (2021-10-26) | -26.81% |
| 6 months (2021-07-26) | -32.93% |
| 1 year (2021-01-26) | -40.06% |
|---|---|
| 2 years (2020-01-22) | N/A |
| 3 years (2019-01-22) | N/A |
| 5 years (2017-01-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -36.73% |
| Return on equity TTM | -63.08% |
| Profit margin | 0% |
| Book value | $7.24 |
| Market capitalisation | $799.2 million |
TTM: trailing 12 months
We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.